Research Article
A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm
Table 1
The overall survival of the training set and validation set in NSCLC patients with a pathological tumor size less than 30 mm.
| Patient characteristics | Training set () | Validation set () | Patients (#) | Patients (%) | OS (months) | Patients (#) | Patients (%) | OS (months) | Median | 95% CI | Median | 95% CI |
| Sex | | | | | | | | | Male | 193 | 42.2 | 92.7 | 85.3-100.0 | 113 | 34.3 | 38.0 | 37.1-38.9 | Female | 264 | 57.8 | 117.4 | 111.5-123.2 | 216 | 65.7 | 38.8 | 38.5-39.1 | Age (y), median (IQR) | 60 (52-66) | | | | 57 (51-65) | | | | <60 | 223 | 48.8 | 114.8 | 108.4-121.2 | 186 | 56.5 | 38.5 | 38.0-39.0 | ≥60 | 234 | 51.2 | 100.8 | 93.8-107.8 | 143 | 43.5 | 38.5 | 38.2-38.9 | Smoking | | | | | | | | | Never smoker | 315 | 68.9 | 114.1 | 108.4-119.7 | 258 | 78.4 | 38.8 | 38.6-39.1 | Current/former smoker | 142 | 31.1 | 91.8 | 83.4-100.1 | 71 | 21.6 | 37.4 | 38.6-39.1 | Preoperational CEA level (ng/mL), median (IQR) | 1.95 (1.28-3.27) | | | | 1.75 (1.14-2.79) | | | | <5.0 | 395 | 86.6 | 108.7 | 103.9-113.4 | 297 | 90.5 | 38.7 | 38.4-39.0 | ≥5.0 | 61 | 13.4 | 82.3 | 68.4-96.2 | 31 | 9.5 | 35.8 | 33.2-38.3 | Type of surgery | | | | | | | | | Lobectomy | 383 | 83.8 | 107.4 | 102.2-112.5 | 127 | 38.6 | 38.7 | 38.4-39.1 | Limited resection | 74 | 16.2 | 91.4 | 78.5-104.3 | 202 | 61.4 | 38.2 | 37.4-38.9 | Tumor location | | | | | | | | | Right upper lobe | 161 | 35.2 | 110.1 | 102.6-117.6 | 118 | 35.9 | NA | | Right middle lobe | 35 | 7.7 | 117.3 | 102.0-132.6 | 34 | 10.3 | | | Right lower lobe | 68 | 14.9 | 87.6 | 75.5-99.6 | 56 | 17.0 | | | Left upper lobe | 124 | 27.1 | 114.1 | 104.4-123.9 | 88 | 26.8 | | | Left lower lobe | 58 | 12.7 | 97.4 | 85.0-109.8 | 31 | 9.4 | | | Undefined | 11 | 2.4 | 72.9 | 43.5-102.2 | 2 | 0.6 | | | Histology | | | | | | | | | AIS & MIA | 195 | 42.7 | 127.6 | 124.8-130.4 | 195 | 59.3 | 38.9 | 38.8-39.1 | IAC | 198 | 43.3 | 97.6 | 89.8-105.4 | 123 | 37.4 | 38.0 | 37.1-38.9 | SCC | 64 | 14.0 | 73.6 | 62.4-84.8 | 11 | 3.3 | 33.2 | 31.7-34.7 | Pathological tumor size (mm), median (IQR) | 15 (9-20) | | | | | | | | ≤10 mm | 156 | 34.1 | 126.0 | 121.5-130.5 | 180 | 54.7 | 38.9 | 38.8-39.1 | >10-20 mm | 196 | 42.9 | 107.3 | 100.6-114.1 | 106 | 32.2 | 38.3 | 37.5-39.1 | >20-30 mm | 105 | 23.0 | 81.3 | 71.1-91.5 | 43 | 13.1 | 37.5 | 35.8-39.1 | Lymph node metastasis | | | | | | | | | N0 | 402 | 88.0 | 114.1 | 109.3-119.0 | 311 | 94.5 | 38.8 | 38.5-39.1 | N1 | 23 | 5.0 | 65.2 | 45.9-84.6 | 5 | 1.5 | 26.9 | 21.5-32.3 | N2 | 32 | 7.0 | 54.4 | 62.4-84.8 | 13 | 4.0 | 34.2 | 31.1-37.3 | Pathological TNM stage | | | | | | | | | 0 | 111 | 24.4 | 128.7 | 126.1-131.2 | 99 | 30.1 | NA | | IA1 | 77 | 16.8 | 110.9 | 100.1-121.7 | 92 | 28.0 | | | IA2 | 138 | 30.2 | 105.5 | 96.8-114.1 | 89 | 27.0 | | | IA3 | 77 | 16.8 | 91.8 | 79.7-104.0 | 31 | 9.4 | | | IIB | 23 | 5.0 | 65.2 | 45.9-84.6 | 5 | 1.5 | | | IIIA | 31 | 6.8 | 54.8 | 42.1-67.5 | 13 | 4.0 | | | P53 expression | | | | | | | | | Negative | 208 | 72.5 | 83.3 | 80.7-85.9 | 211 | 75.1 | 38.8 | 38.5-39.1 | Positive | 79 | 27.5 | 68.2 | 61.2-75.2 | 70 | 24.9 | 36.5 | 35.2-37.7 | Ki-67 expression | | | | | | | | | <10% | 203 | 70.7 | 84.2 | 81.4-87.1 | 186 | 65.7 | 38.9 | 38.7-39.1 | ≥10% | 84 | 29.3 | 67.6 | 61.2-74.0 | 97 | 34.3 | 37.6 | 36.5-38.7 | EGFR mutation | | | | | | | | | Wild type | 190 | 70.9 | 76.9 | 74.8-78.9 | 182 | 55.7 | 38.3 | 37.7-38.9 | Mutation | 78 | 29.1 | 71.4 | 64.7-78.0 | 145 | 44.3 | 38.8 | 38.4-39.2 |
|
|
IQR: interquartile range; CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma; SCC: squamous cell lung cancer; EGFR: epidermal growth factor receptor.
|